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The global distribution of lymphatic filariasis, 2000–18: 
a geospatial analysis
Local Burden of Disease 2019 Neglected Tropical Diseases Collaborators*
Summary
Background Lymphatic filariasis is a neglected tropical disease that can cause permanent disability through disruption 
of the lymphatic system. This disease is caused by parasitic filarial worms that are transmitted by mosquitos. Mass 
drug administration (MDA) of antihelmintics is recommended by WHO to eliminate lymphatic filariasis as a public 
health problem. This study aims to produce the first geospatial estimates of the global prevalence of lymphatic 
filariasis infection over time, to quantify progress towards elimination, and to identify geographical variation in 
distribution of infection.
Methods A global dataset of georeferenced surveyed locations was used to model annual 2000–18 lymphatic filariasis 
prevalence for 73 current or previously endemic countries. We applied Bayesian model-based geostatistics and time 
series methods to generate spatially continuous estimates of global all-age 2000–18 prevalence of lymphatic filariasis 
infection mapped at a resolution of 5 km² and aggregated to estimate total number of individuals infected.
Findings We used 14 927 datapoints to fit the geospatial models. An estimated 199 million total individuals 
(95% uncertainty interval 174–234 million) worldwide were infected with lymphatic filariasis in 2000, with totals for 
WHO regions ranging from 3·1 million (1·6–5·7 million) in the region of the Americas to 107 million (91–134 million) 
in the South-East Asia region. By 2018, an estimated 51 million individuals (43–63 million) were infected. Broad 
declines in prevalence are observed globally, but focal areas in Africa and southeast Asia remain less likely to have 
attained infection prevalence thresholds proposed to achieve local elimination.
Interpretation Although the prevalence of lymphatic filariasis infection has declined since 2000, MDA is still necessary 
across large populations in Africa and Asia. Our mapped estimates can be used to identify areas where the probability 
of meeting infection thresholds is low, and when coupled with large uncertainty in the predictions, indicate additional 
data collection or intervention might be warranted before MDA programmes cease.
Funding Bill & Melinda Gates Foundation.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY 4.0 license.
Introduction
Lymphatic ilariasis is a parasitic infection caused by the 
ilarial nematodes Wuchereria bancrofti, Brugia malayi, and 
Brugia timori.1 These parasites are transmitted by 
members of several mosquito genera, particularly 
Anopheles, Aedes, Culex, and Mansonia, with geographic 
variation in the identity of dominant vectors.2 Long-term 
infection can cause deterioration of the lymphatic 
system, characterised by severe swelling of the limbs 
(lymphoedema) and later elephantiasis or lymphoedema 
of the scrotum (hydrocele). Community-level trans-
mission of infection can be inter rupted1 by mass treatment 
with recommended oral regimens of the antihelmintic 
medicines albendazole, either alone or with ivermectin, 
or diethylcarbamazine citrate and albendazole, or a 
combination of all three, depending on the setting. These 
medicines are given in mass public health campaigns or, 
in certain settings, through salt fortiication with 
diethylcarbamazine citrate. Treat ment of at least 65% of 
the total population in endemic areas for at least 
5–7 consecutive years through annual or biannual mass 
drug administration (MDA) is recom mended by WHO, to 
reduce the reservoir of micro ilaraemia and antigenaemia 
among humans, with the ultimate goal of interrupting 
transmission to eliminate lymphatic ilariasis as a public 
health problem.3,4 WHO has recommended guidelines5 by 
which national elimination of lymphatic ilariasis as a 
public health problem can be validated, and national 
programmes are requested to submit dossiers to 
document baseline prevalence, programme interventions 
and monitoring activities, prevalence during surveillance 
after MDA, and availability of care for people with 
lymphatic ilariasis.
Lymphatic ilariasis transmission has been 
documented throughout Africa, southeast Asia, and the 
Paciic, as well as in focal areas in the Caribbean, South 
America, and the Middle East.6 Use of population-level 
vector control or MDA began in the 1950s in India, 
China, Egypt, and Brazil, followed by implementation 
across Oceania7 from the 1960s to the 1990s. In 1997, 
the World Health Assembly recognised the goal of 
global elimination of lymphatic ilariasis as a public 
health problem by 2020 under resolution WHA50.29,8 
in which national programmes would aim to interrupt 
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trans mission and control mor bidity. Elimination of 
lymphatic ilariasis as a public health problem was irst 
achieved in China in 2007 and South Korea in 2006.9,10 
Coordinated eforts between ministries of health, 
international part ners, and the research community 
under the auspices of the Global Programme to 
Eliminate Lymphatic Filariasis (GPELF)11 have been 
ongoing since WHO launched the programme in 2000. 
With the adoption of the London Declaration in 2012, 
the global community reinforced its commitment to 
elimination. New milestones and targets for elimination 
of lymphatic ilariasis as a public health problem have 
been proposed by WHO12 in line with 2030 objectives 
for Sustainable Development Goals.
From the late 1990s onwards, most national lymphatic 
ilariasis elimination programmes implemented some 
form of baseline mapping to identify implementation 
units eligible for MDA, such as districts or counties. 
Eligibility for MDA was generally determined by 
infection prevalence of more than 1%, measured by 
night blood smears to detect microilaraemia, detection 
of circulating ilarial antigen, or presence of known or 
suspected ilarial lymphoedema and hydrocele cases. 
Global guidelines for monitoring and evaluation of these 
programmes were irst adopted in 2000,13 followed by 
updates in 2005,14 and 2011.3 Monitoring of MDA is 
conducted through periodic sentinel site and spot check 
surveillance, and current guidelines recommend the 
Transmission Assessment Survey to determine if 
implementation units can enter the post-MDA 
surveillance phase. As of 2018, 21 lymphatic ilariasis 
elimination programmes have begun post-MDA 
surveillance for all implementation units considered 
endemic, including 15 that have met validation criteria 
for having eliminated lymphatic ilariasis as a public 
health problem.15 51 countries or territories with ongoing 
lymphatic ilariasis elimination programmes remain, 
15 of which have yet to reach full geographic coverage 
with MDA as of 2018.15
Despite the broad scale of lymphatic ilariasis data 
collection since the inception of the GPELF, previous 
global infection prevalence estimates relied on older 
data; estimates for 1996,6,16 2000,17 and 201317 were based 
on data extracted from 118 studies published between 
1953 and 1991 for national-level analysis.16 Although other 
studies have employed geostatistical methods in 
lymphatic ilariasis-related research, including estimates 
of population at risk18 and pre-control prevalence,19 tests 
for spatial clustering,20 country-level prevalence,16,21 and 
forecasted future prevalence in Africa,22,23 no previous 
analysis has used geospatial methods to estimate time 
trends in global infection prevalence accounting for sub-
national variation in covariates associated with lymphatic 
ilariasis transmission. We therefore aimed to estimate 
the global prevalence of lymphatic ilariasis to relect the 
progress achieved after two decades of the GPELF and 
identify areas that might warrant additional programme 
investment to reach elimination goals by 2030.
Research in context
Evidence before this study
A systematic review of literature was done to identify previous 
global estimates of lymphatic filariasis infection. The first global 
estimate of lymphatic filariasis prevalence, published in 1996, 
estimated 83 million people infected, with an additional 
42 million living with hydrocele or lymphoedema. This estimate 
was then updated in 2000 to account for population growth, 
suggesting a total of 130 million infections. The most recent 
global analysis was done for 2013, in which 68 million 
individuals were estimated to be infected. The 2013 estimate 
accounted for national-level coverage of mass drug 
administration, extrapolating from the 2000 estimate. 
These three estimates all relied on the same lymphatic filariasis 
prevalence data inputs published between 1953 and 1991. 
While this series of estimates showed significant reductions in 
lymphatic filariasis infection over time, they did not use data 
collected since the inception of the Global Programme to 
Eliminate Lymphatic Filariasis (GPELF), nor did they account for 
subnational variation in the distribution of infection.
Added value of this study
We compiled a georeferenced lymphatic filariasis infection 
prevalence dataset from the GPELF, published scientific 
literature, and ministry of health data, to which we applied 
model-based geostatistics and time series methods. 
We estimate 2000–18 global all-age prevalence of lymphatic 
filariasis infection, with corresponding measures of 
uncertainty. We also present the posterior probability that 
various infection thresholds proposed to achieve elimination 
have been reached. Our model improves upon previous efforts 
by using a time series perspective not included in earlier global 
estimates, accounting for subnational variation in baseline 
endemicity and mass drug administration and insecticide-
treated net distribution. This study is also the first to 
implement diagnostic and age adjustments to account for 
variability in programmatic data collection over the course of 
implementation.
Implications of all the available evidence
Although lymphatic filariasis prevalence substantially declined 
from 2000 to 2018, it is likely that not all areas will achieve the 
GPELF targets by the original goal of 2020. This time series 
analysis quantifies progress towards elimination since 2000. 
National programmes and implementing partners can use 
these geospatial estimates to identify areas that might require 
additional surveillance or intervention to act on the two 
components of the global elimination strategy: interrupting 
transmission and controlling morbidity in affected populations.
Articles
www.thelancet.com/lancetgh   Vol 8   September 2020 e1188
Methods
Search strategy and selection criteria
We did a systematic review of the published literature to 
identify lymphatic ilariasis prevalence data. We searched 
PubMed, Web of Science, and Scopus for all articles 
published between database inception and Oct 14, 2016 
(supplemented with a later search for articles published 
before Oct 24, 2018) with the following keywords: 
“lymphatic ilariasis”, “prevalence”, “incidence”, “mass 
drug administration”, “coverage”, “lymphoedema”, 
“hydrocele”, “transmission assessment survey”, and 
“mapping”. Additional programme monitoring data were 
obtained from WHO under the auspices of the GPELF 
and the Expanded Special Project for Elimination of 
Neglected Tropical Diseases. We compiled data from 1990 
onwards in order to model infection prevalence from 2000 
to 2018. We included publications that reported prevalence 
of lymphatic ilariasis antigenaemia or microilaraemia, 
with sample sizes, location of data collection, and method 
of diagnosis indicated. We excluded publications that only 
reported data collected before 1985 or results of case-
control studies or qualitative research or that were 
duplicates of existing data sources. Subnational data were 
georeferenced to the smallest geographic unit possible, 
typically at the community or implementation unit level. 
We extracted the survey year, data type (eg, baseline 
mapping or Transmission Assessment Survey), site-
speciic geographic identii cation information (ie, name of 
community or district), age range of individuals tested, 
number tested, number of individuals positive, and 
diagnostic test used (appendix 2 pp 6–40).
Geospatial covariates
All statistical analysis was done using R version 3.5.1. 
Because our modelling framework emphasises predic-
tion, we sought to include a range of covariates that could 
be associated (even indirectly) with lymphatic ilariasis 
infection, in order to span ecological, demographic, and 
programmatic determinants of transmission. Covariates 
were tested to maximise prediction and do not assume a 
speciic causal mechanism. We chose environmental 
factors, such as elevation, precipitation, and temperature, 
as well as socioeconomic measures potentially associated 
with vector-borne diseases, such as Human Development 
Index24 and under-5 mortality.25 Population coverage with 
insecticide-treated nets,26,27 indoor residual spraying28 (for 
Africa), and lymphatic ilariasis MDA (of any drug 
regimen) interventions known to reduce transmission, 
and malaria (Plasmodium falciparum and Plasmodium 
vivax) prevalence and incidence were included as proxies 
for exposure to Anopheles spp mosquitoes, because they 
are vectors of Plasmodium spp and W bancrofti in some 
lymphatic ilariasis-endemic regions. Antimalarial treat-
ment coverage was included for Africa to account for 
changes in malaria burden that are unrelated to inter-
ventions that afect lymphatic ilariasis. Time-variant 
covariates were extracted to their corresponding model 
years, with the following exceptions: single-year time lags 
were applied to some covariates hypothesised to have a 
lagged temporal relationship with lymphatic ilariasis 
prevalence, and when speciic years of data were 
unavailable, the nearest available year of data was used. 
Variance Inlation Factor analysis was used to exclude 
redundant covariates (appendix 2 pp 41–49). The efects of 
covariates in model it are presented in appendix 2 
(pp 78–81).
Age and diagnostic adjustment
We used age and diagnostic models to adjust input data 
before the main analysis, yielding adjusted estimates of 
all-age (0–94 years) infection prevalence in both sexes 
combined (male and female), as measured by the 
immunochromatographic diagnostic test (antigenaemia 
model) or microilariae observation (microilaraemia 
model). Owing to the introduction and rapid adoption of 
immunochromato graphic test card assessments in the 
mid-2000s and their higher sensitivity than microilariae 
observation, data derived from identiication of micro-
ilaraemia by blood microscopy were irst adjusted to be 
comparable with immuno chromatographic test esti-
mates of ilariasis prevalence (and vice versa for the 
microilaraemia model). Prevalence measured in a 
single age group (such as children in the Transmission 
Assessment Survey) were adjusted to relect all-age 
prevalence. To develop these crosswalk models, we 
identiied peer-reviewed published surveys that reported 
prevalence of ilariasis antigenaemia (immunochromato-
graphic test or Filariasis Test Strip) or microilaraemia 
(W bancrofti or Brugia spp) in multiple age groups in the 
same study population. The age-dependent relationship 
between prevalence of microilaraemia and antigenaemia 
(as determined by immunochromatographic test) was 
then calculated using surveys that reported both 
measures by itting a logistic regression model (whose 
outcome measure is the log-odds of infection 
proportion—ie, cases over sample size), with a basis 
spline on the ratio of antigenaemia to microilaraemia 
preva lence by age, to accommodate potential non-
linearity in this relationship. Estimated age-speciic 
ratios were then applied to reported microilaraemia 
prevalence data in the geospatial modelling dataset to 
obtain corresponding estimates of immunochromato-
graphic test prevalence. We estimated age-speciic 
prevalence of infection by itting a logistic regression 
model with study population-level ixed efects and a 
basis spline on age using surveys reporting prevalence 
of antigenaemia  (immunochromato graphic test or 
Filariasis Test Strip) or microilaraemia for multiple age 
groups. This estimated prevalence-by-age curve was 
then compared with each datapoint in the full model-
based geostatistics modelling dataset to derive scaling 
factors, with which the curve was adjusted to yield 
the corresponding esti mates of all-age prevalence. 
Coeicients for all models used for age or diagnostic 
See Online for appendix 2
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adjustment were inferred using maximum likelihood 
optimisation (appendix 2 pp 50–119).
Geostatistical analysis 
Separate Bayesian geostatistical models were it for each 
of the following modelling regions, based on a review of 
lymphatic ilariasis endemicity (appendix 2 pp 13–40): 
Africa and Yemen (including Madagascar, São Tomé and 
Príncipe, and Comoros), south Asia (India, Sri Lanka, 
Nepal, and Bangladesh), southeast Asia, and the island of 
Hispaniola. For the geostatistical models, we irst used 
an ensemble method29 that combines the strengths of 
diferent modelling frameworks and can improve 
predictive performance, itting three submodels to 
predict lymphatic ilariasis prevalence in each modelling 
region: generalised additive models (binomial model), 
generalised boosted models (Poisson model), and lasso 
regression (empirical logit model). All submodels were 
it to covariate values extracted at the year and coordinates 
of georeferenced datapoints and included country-level 
ixed efects.
Our full model of lymphatic ilariasis infection 
prevalence consisted of a spatially and temporally explicit 
generalised linear mixed efects model through integrated 
nested Laplace approximation,30 it using the R-INLA 
package,31 with a binomial likelihood model and 
minimally informative priors (appendix 2 p 62). Out-of-
sample predictions from the three submodels were used 
as covariates, with a sum-to-one constraint (efectively 
incorporating a weighted average of these submodel 
outputs), and models included country random efects 
and a nugget variance term to account for very small-scale 
variation. Residual spatiotemporal variation was modelled 
as a spatiotemporal Gaussian process. Stochastic partial 
diferential equations were used to model the spatial 
process, with a Matérn spatial covariance function. 
Temporal covariance was modelled using a irst-order 
autoregressive function. Predictions were generated at 
the 5-km² resolution using the in-sample submodel 
predictions as covariates, with 1000 samples drawn from 
the joint posterior distributions to account for covariance 
among model parameters; predictions were summarised 
by their means and 95% uncertainty interval (UI; 
generated from the 2·5th and 97·5th percentiles). To 
assess the contribution of temporal efects, an additional 
time-stationary (but otherwise identical) geospatial model 
was it to each region; the in-sample and out-of-sample 
behaviour of these time-stationary models was compared 
with the corresponding spatiotemporal models to select a 
inal model for each region. The posterior probabilities 
that prevalence was less than 1% or 2% in 2018 were 
calculated at 5-km² resolution using the 1000 samples; 
these thresholds represent crucial values for decision 
making for cessation of MDA in lymphatic ilariasis 
elimination programmes.3
Geostatistical methods were not practical for the 
following locations, owing to small area (<25 km²), 
missing covariate data, or limited georeferenced data: 
American Samoa, Brazil, Cook Islands, Federated States 
of Micronesia, Fiji, French Polynesia, Guyana, Kiribati, 
Maldives, Marshall Islands, New Caledonia, Niue, Palau, 
Samoa, Tonga, Tuvalu, Vanuatu, and Wallis and Futuna. 
Instead, Bayesian time series models (irst order 
autoregressive or random walk models) were used to it 
annual national prevalence (appendix 2 pp 117–119). 
Estimation of case totals is described in appendix 2 
(pp 64–77). Each geostatistical model was run ten times, 
each time holding out data from one spatially stratiied 
fold, to generate out-of-sample predictions. Out-of-sample 
performance was examined by mean bias, mean absolute 
error, root mean square error, 95% data coverage within 
prediction intervals, and correlations of observed (held-
out data) to predicted values.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had inal responsibility for 
the decision to submit for publication.
Results
We used a total of 15 829 georeferenced survey locations 
to it our models. 14 927 datapoints were used to it the 
geospatial models, of which 13 492 (90·1%) were 
georeferenced to speciic coordinates and 1435 (9·6%) 
could only be georeferenced to areal units, such as 
districts or counties. 9942 (66·6%) datapoints reported 
2000 2005 2010 2018
African region 74 806 947 (59 751 659–93 547 156) 53 285 936 (41 433 633–66 593 897) 22 699 590 (17 650 038–29 487 073) 10 142 514 (6 732 523–15 631 274)
Region of the Americas 3 115 289 (1 557 956–5 667 033) 1 296 451 (686 440–2 270 334) 470 720 (223 958–946 375) 368 629 (153 412–812 803)
Eastern Mediterranean 
region
3 684 550 (2 148 922–6 804 707) 1 169 399 (397 804–3 694 354) 1 711 945 (750 046–3 718 240) 982 521 (166 924–3 347 885)
South-East Asia region 106 819 113 (90 789 357–134 298 186) 85 737 230 (74 067 271–101 995 083) 50 694 194 (42 897 155–63 174 481) 36 783 583 (30 601 450–46 532 997)
Western Pacific region 8 967 559 (3 165 419—21 686 740) 4 768 730 (2 139 517–11 748 685) 4 242 981 (1 470 866–11 528 780) 2 568 909 (1 042 163–6 234 225)
Total 198 758 026 (174 061 903–234 011 832) 147 319 711 (130 326 019–167 892 148) 80 279 264 (69 142 381–96 315 543) 51 417 924 (42 885 379–63 414 821)
Data are mean (95% uncertainty interval). We did not estimate the number of individuals with lymphatic filariasis for the European region.
Table: Estimate of individuals with lymphatic filariasis, by WHO region
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lymphatic ilariasis prevalence by immunochromato-
graphic test, 4120 (27·6%) by microilaraemia, and 
865 (5·8%) by other diagnostic methods (Filariasis Test 
Strip, Brugia Rapid, etc). An additional 1037 inputs were 
used to generate estimates of infection prevalence for 
locations for which model-based geostatistics were 
infeasible.
We estimated a total of 199 million infections in 2000 
(95% UI 174–234 million), with totals for WHO regions 
ranging from 3·1 million (1·6–5·7 million) in the region 
of the Americas to 107 million (91–134 million) in the 
South-East Asia region (table). The estimated global 
burden in 2000 was concentrated in the South-East Asia 
region, with 52% of the total global number of individuals 
infected derived from estimates for Bangladesh, India, 
Indonesia, and Myanmar combined. In Africa, Nigeria, 
Tanzania, Mozambique, and the Democratic Republic of 
the Congo comprised around 21% of the 2000 global 
estimate. The mapped estimated prevalence across 
Africa for 2000, 2005, 2010, and 2018 (igure 1) shows a 
Figure 1: Prevalence of lymphatic filariasis antigenaemia in Africa and Yemen at a 5 km² resolution
Mean predictions of lymphatic filariasis antigenaemia (infection) prevalence from the Bayesian geostatistical model for 2000, 2005, 2010, and 2018 in Africa and 
Yemen, as measured by the immunochromatographic test. Areas for which prevalence exceeded 1% in 2000 would have resulted in the implementation unit (typically 
a district) qualifying for mass drug administration. Hatch-marks indicate countries for which estimates are not produced. Grey areas are masked on the basis of sparsely 
populated areas (fewer than 10 people per 1 km² grid cell) and barren landscape classification. Interactive visualisation tool available online.
[A1]
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general decrease in lymphatic ilariasis prevalence over 
the 19-year period. Globally, the number of individuals 
infected reduced by 74%, to an estimated 51 million 
(43–63 million) in 2018 (table). In 2018, the global burden 
of infection was still mostly concentrated in southeast 
Asia (igure 2). Although the contribution to the total 
number of infections is driven by the large population of 
these countries, countries in coastal west Africa and 
central Africa, as well as Papua New Guinea, continued 
to have the highest national prevalence estimates in 2018. 
Applying diferent grid-cell-level population thresholds 
to exclude urban popu lations from the total estimates 
of infected individuals resulted in lower regional totals, 
largely in the South-East Asia region (appendix 2 
pp 110–116). Uncertainty of predictions are illustrated 
in appendix 2 (pp 64–77), which show wider UIs in the 
earlier time periods and locations for which limited or 
no data were available, particularly for locations such 
as the Democratic Republic of the Congo that did not 
implement baseline mapping until the latter half of our 
time series. Results of out-of-sample model validation 
are presented in appendix 2 (pp 92–119).
In Asia, the largest subnational variations in the model 
estimates were predominantly in areas in Indonesia, as 
well as in Papua New Guinea and Myanmar. Districts in 
the Central African Republic and Côte d’Ivoire were 
consistently estimated to have among the highest infection 
prevalence in both 2000 and 2018. Areas of Indonesia and 
Papua New Guinea represent a large proportion of the 
lymphatic ilariasis infection prevalence in both 2000 and 
2018. By contrast, Thailand, Laos, Cambodia, and Vietnam 
had among the lowest prevalence estimates of the 
countries we modelled, consistent with the focal nature of 
transmission in those settings and the achievement of 
elimination goals. Our results relect notable progress 
towards elimination, as documented in settings such as 
Haiti, Bangladesh, Cambodia, Egypt, Malawi, Thailand, 
and Togo (igures 1, 2; appendix 2 pp 64–67). In Africa, 
the 2018 predictions highlight subnational variation in 
lymphatic ilariasis infection prevalence that persists in 
west and central Africa. Although subnational predictions 
suggest potential for lymphatic ilariasis transmission 
in some areas historically considered non-endemic, such 
as northern Kenya, these estimates have very large 
uncertainty, because no data from after 1990 were available 
for inclusion in the model.
The posterior probability that the prevalence of 
lymphatic ilariasis by immunochromatographic test was 
>30%
>20–30%
>10–20%
>5–10%
>2–5%
>1–2%
0–1%
Prevalence of  lymphatic filariasis
2000
2010
2005
2018
Figure 2: Prevalence of lymphatic filariasis antigenaemia in south and southeast Asia at a 5 km² resolution
Mean predictions of lymphatic filariasis antigenaemia (infection) prevalence from the Bayesian geostatistical model for 2000, 2005, 2010, and 2018 in south and 
southeast Asia, as measured by the immunochromatographic test. Areas for which prevalence exceeded 1% in 2000 would have resulted in the implementation unit 
(typically a district) qualifying for mass drug administration. Hatch-marks indicate countries for which estimates are not produced. Grey areas are masked on the basis 
of sparsely populated areas (fewer than 10 people per 1 km² grid cell) and barren landscape classification. Interactive visualisation tool available online.
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less than 1% at the 5-km² resolution varied considerably 
throughout much of central Africa and coastal west 
African countries in 2018 (igure 3). Areas in Ghana, 
Liberia, northern Democratic Republic of the Congo, and 
Côte d’Ivoire are unlikely to be below this threshold as of 
2018. These areas were predicted to be among those with 
the highest prevalence in 2000, suggesting that higher 
prevalence in 2000 or more recent programme initiation 
is predictive of locations that still require MDA. Other 
regions and results for a 2% threshold are presented in 
appendix 2 (pp 68–72).
Discussion
Overall, our results demonstrate the success of the GPELF, 
relecting the contribution of donated thera peutics and 
community-based public health interventions to achieving 
elimination of a disease that is prevalent among some of 
the most resource-limited settings in the world. We 
estimate that more than 198 million individuals were 
infected globally in 2000, suggesting a greater burden than 
the around 130 million individuals previously quantiied.17 
The 2018 estimate of around 51 million infected individuals 
relects the progress achieved thus far towards the 
elimination of lymphatic ilariasis as a public health 
problem. Our results are consistent with elimination goals 
as reported in settings such as Egypt,32 Togo,33 Malawi,34 
Cambodia,35 Yemen,36 and several Paciic Island nations.37–40 
Our analysis accounts for subnational variability in 
environ mental covariates and MDA. From the program-
matic perspective, the 2018 estimates identify areas for 
sustained investment, to ensure existing MDA activities 
continue, and potential areas for conirmatory mapping. 
National lymphatic ilariasis elimination programmes 
typically follow pro gramme monitoring guidelines that 
use decision rules on the basis of implementation unit-
level data to determine whether MDA should commence, 
continue, or cease. Given the huge investment in global 
monitoring for lymphatic ilariasis elimination, there is 
merit to using geospatial analysis for secondary evaluation 
of these data. Although traditional monitoring approaches 
are still integral to programme implementation, they 
depend on ield-based data collection for each individual 
implemen tation unit to inform decision making, and do 
not enable national programmes to integrate data from 
similar settings to update estimates of programme 
progress. We present a speciic use case, in which we 
calculate the posterior probability that a given prevalence 
threshold has been met, to identify subnational areas that 
might pose a threat to achieving elimination goals, which 
also accounts for uncertainty. In these locations, national 
programmes might wish to consider prioritising areas for 
data collection or additional MDA before dismantling 
programme infrastructure.
Although this global analysis improves upon previous 
estimates for lymphatic ilariasis, data coverage is sparse 
compared with geospatial analyses of other indicators.25 
Lymphatic ilariasis prevalence data are generally 
collected for the purpose of MDA implementation, 
whereas data on indicators such as under-5 mortality 
monitor progress towards many targets and are therefore 
common in national household surveys. Data from 
before 2000 might be subject to bias due to purposive 
sampling, and data quality has probably improved over 
time. Global guidelines for lymphatic ilariasis data 
collection recommend small sample sizes for 
community-level surveys, usually 50–100 indi viduals, 
which adds additional uncertainty. We chose not to 
incorporate lymphatic ilariasis endemicity status into 
our model to avoid circularity. As a result, a few settings 
(such as northern Kenya, southern Cambodia, or central 
Thailand) are known to be non-endemic, for which 
national programmes might not have implemented 
recent data collection activities or published any data, 
and our UIs relect this. Mean estimates of infection 
prevalence can be greatly afected by extreme predictions 
among the 1000 iterations, so these results should be 
interpreted alongside uncertainty, noting that UIs are 
wide in data-sparse locations. We were unable to account 
for vector density, parasite aggregation, or annual biting 
rates, because these covariates are not available for all 
modelling regions. Although we present probabilities 
that locations have achieved various thresholds of 
infection, these should not be interpreted as evidence for 
the elimination of transmission; rather, low probabilities 
Figure 3: Posterior probability that all-age lymphatic filariasis antigenaemia 
prevalence was below 1% at a 5 km² resolution in Africa and Yemen, 2018
Mean predictions of posterior probability that all-age lymphatic filariasis 
antigenaemia (infection) prevalence was below 1% in a given 5 km² grid cell 
from the Bayesian goestatistcal model for 2018 in Africa and Yemen, as 
measured by the immunochromatographic test. Hatch-marks indicate countries 
for which estimates are not produced. Grey areas are masked on the basis of 
sparsely populated areas (fewer than 10 people per 1 km² grid cell) and barren 
landscape classification. Interactive visualisation tool available online.
Probability of 
lymphatic filariasis
prevalence <1%
>95%
50%
<5%
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could serve as a signal to target additional supervision or 
data collection activities and to highlight uncertainty in 
the mean infection estimates. Our methods for 
diagnostics and age adjustment relied on evidence from 
peer-reviewed literature, with a single age and diagnostic 
adjustment. Detection of antigenaemia often results in 
higher prevalence compared with infection measured by 
microilaraemia, because antigen-based diagnostics 
detect the presence of the adult worm. In settings where 
diethylcarbamazine citrate is included in MDA, the 
partial macroilaricidal efects of treatment and the 
lifespan of the worms might result in detection of dead 
adult worms. We did not account for possible cross-
reactivity due to Loa loa infection. We were unable to 
identify suicient comparisons to model the age pattern 
after MDA and the pharmaco kinetics of drug regimens. 
It is plausible that age-speciic prevalence varies based on 
location-speciic patterns in MDA participation.
Most lymphatic ilariasis burden estimates have either 
relied on national-level analysis or presented the 
situation before control programmes started.19 National-
level analyses do not leverage information from detailed 
geospatial data sources that now exist for a wide range of 
covariates, nor do they display subnational variation in 
prevalence. Presentation of data from before control 
programmes started generates a cross-sectional estimate 
of the distribution of infection prevalence that does not 
account for secular trends, population shifts, and 
temporal variation in initiation of MDA by imple-
mentation units to estimate prevalence for speciic years. 
Our geostatistical models allow the breadth of the 
lymphatic ilariasis data landscape to generate 
predictions for areas that are less data rich and have 
programmatic implications. This analysis serves both to 
quantify the gains achieved towards elimination and to 
identify areas for which additional data collection or 
intervention might be warranted before MDA 
programmes cease.
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